• Consolidated profit was up 48.5% YoY at Rs 938.8 cr. • Consolidated revenue was at Rs 12,454 cr, up 4.1% YoY. • EBITDA was up 3.2% YoY at Rs 1,927.7 cr. • Board has recommended a dividend of Rs 2/share.
• Standalone net profit was up 37% YoY at Rs 859 cr. • Revenue rose 12% YoY at Rs 8,307 cr. • EBITDA rose 30.9% YoY to Rs 1,083 cr. • Margins expanded to 13% from 11.2% YoY. • Board has declared a final dividend of Rs 35/share.
Zydus Lifesciences gets USFDA final nod for Sucralfate tablets USP, 1 gm, which are used to treat and prevent the return of Duodenal ulcers.
Swipe Up
Check More Details